The HCPLive Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...
December 26th 2024
From groundbreaking therapies to ethical dilemmas, HCPLive’s top podcasts of 2024 delivered expert insights and human stories across medicine.
‘REEL’ Time Patient Counseling™: Navigating the Complex Journey of Diagnosing and Managing Fabry Disease
View More
Expert Illustrations & Commentaries™: Envisioning Novel Therapeutic Approaches to Managing ANCA-associated Vasculitis
View More
Clinical Consultations™: Addressing Elevated Phosphate Levels in Patients with END-STAGE Kidney Disease (ESKD)
View More
Hospitals Receive New Checklists in 10 Patient Safety Areas
The federal government's Partnership for Patients Hospital Engagement Networks (HENs), which work to improve patient care through implementation and dissemination of best practices in clinical quality, have released checklists for 10 areas of patient care.
High Rates of In-Hospital Cardiac Arrest Likely to Correlate with Poor Survival
Recent research from the University of Michigan Health Systems published in JAMA Internal Medicine found that hospitals with the highest rates of cardiac arrests are more likely to have the poorest survival rates for those cases.
Universal Decolonization Significantly Lowers MRSA Rates in ICU Patients
The largest study to date on reducing rates of methicillin-resistant Staphylococcus aureus (MRSA) infections in ICU patients found that bloodstream infections in these patients can be reduced by more than 40 percent through universal decolonization practices.
Extreme Glycemic Control Not Significantly Associated with Increased All-Cause Mortality
June 24th 2013While the current ADA guidelines recommend targeting HbA1c levels to below 8% for high-risk patients with diabetes, reducing the level to 5.7% dose not raise CVD or overall mortality risk, according to a recent study.
Combination Liraglutide and Insulin Degludec Is Safe and Effective in Type 2 Diabetes
June 23rd 2013Study shows a combination of liraglutide and the genetically modified insulin analog degludec was safe and improved HbA1c levels, weight loss, and hypoglycemia outcomes in patients with type 2 diabetes.
Promising Heart Failure Drug Receives ‘Breakthrough' FDA Designation
The US Food and Drug Administration has awarded "breakthrough therapy" status to a synthetic copy of a naturally occurring human hormone for the treatment of acute heart failure (AHF), drug developer Novartis announced today.
The Educated Patient® Diabetes Resource Guide
June 21st 2013The Diabetes Resource Guide highlights 20 websites that feature articles on topics such as ways to address and improve lifestyle factors (such as diet), how to live day to day with diabetes, information about diabetes medications, online forums, and more.